Check out what is happening in the science and entrepreneurial community this month! https://t.co/gkKsYg8frG
According to research, the primary reason cited by investors for lack of funding is "excessive risk." The reality is that many early-stage investors simply lack the technical expertise needed to evaluate risk, and, therefore, most regions under-invest in early stage companies.
BioAccel’s portfolio to date has resulted in a current book value of the portfolio that exceeds $98.3M with a proje… https://t.co/JXLkVK2p4G
One of our portfolio partners, LIfe365, added two new board of advisor members. We are pleased to welcome Ron Diamo… https://t.co/907neCp7Cw
While BioAccel uses philanthropic funding to bridge the Valley of Death stage of business development unique to bioscience innovation, our novel nonprofit status also allows the holding of equity in exchange for early-stage investments, which ensures our long-term sustainability.
This work is critically important for U.S. competitiveness because if the U.S.were able to commercialize only 6 per… https://t.co/r0slg4duM9
Based in metropolitan Phoenix, Arizona, BioAccel accelerates the development of new companies and biomedical produc… https://t.co/kAmr1T8bbi
BioAccel is the only 501(c)3 organization in the Southwestern United States that fulfills a mission to drive econom… https://t.co/KvLM6fKSEA
Where 33 other states had deployed seed capital funds by 2013, Arizona has none. The need to establish multiple ear… https://t.co/gR3vklJRJc
